Pricing Log in Create free account

Gossamer Bio, Inc. (GOSS) vs Xilio Therapeutics, Inc. (XLO)

Gossamer Bio, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Gossamer Bio, Inc. and Xilio Therapeutics, Inc. are of similar size ($57.6M and $55.9M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against 32.4%. Xilio Therapeutics, Inc. has the higher net margin (−34.1% vs −235.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Xilio Therapeutics, Inc. leads on 10 and Gossamer Bio, Inc. on 4.

Valuation

Metric GOSS XLO Biotechnology median
P/E n/m n/m 10.60
P/S 0.73 2.61 9.40
P/B n/m 2.32 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.07 0.51 9.02
Earnings yield (467.69%) (17.27%) (32.88%)
Free cash flow yield (417.17%) (36.59%) (23.13%)

Profitability

Metric GOSS XLO Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (311.70%) (48.94%) 0.00%
Net margin (235.00%) (34.06%) 0.00%
Free cash flow margin (305.19%) (95.59%) 0.00%
Return on equity 178.72% (55.03%) (51.96%)
Return on assets (78.81%) (15.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GOSS XLO Biotechnology median
Revenue growth (TTM) 32.43% 327.25% 6.76%
EPS growth (last fiscal year) (200.00%) 72.55% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GOSS XLO Biotechnology median
Debt to equity (0.38) 0.00 0.00
Current ratio 0.53 4.25 4.97
Net debt to EBITDA (0.35) 3.40 1.01

Dividend

Metric GOSS XLO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GOSS XLO Biotechnology median
Market cap 57.56m 55.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack